Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis
Open Access
- 27 May 2013
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 17 (3) , R97
Abstract
Introduction: Severe sepsis is associated with an unacceptably high rate of mortality. Recent studies revealed elevated levels of vascular endothelial growth factor (VEGF), a potent angiogenic and vascular permeability factor, in patients with sepsis. There was also an association between VEGF levels and sepsis severity. Here we investigate the effects of an anti-VEGF antibody (Bevacizumab, Bev) in an experimental model of sepsis. Methods: Human umbilical vein endothelial cells (HUVECs), murine cecal ligation and puncture (CLP), and endotoxemia models of sepsis were used. HUVECs were treated with lipopolysaccharide (LPS) and/or Bev, harvested and cytokine mRNA levels determined using a semi-quantitative reverse transcription-polymerase chain reaction assay. The levels of inflammatory cytokine were also determined in HUVECs supernatants. In addition, the effects of Bev on mortality in the CLP and endotoxemia models of sepsis were evaluated. Results: Treatment with Bev and LPS significantly decreased the expression and the level of inflammatory cytokines in HUVECs relative to LPS alone. In CLP and endotoxemia models, survival benefits were evident in mice given 0.1 mg/kg of Bev relative to the CLP or LPS alone (P P = 0.028, respectively), and in 6 h post-treated mice relative to the CLP alone for the effect of different time of Bev (P = 0.033). In addition, Bev treatment inhibited LPS-induced vascular leak in the lung, spleen and kidney in the murine endotoxemia model (P <0.05). Conclusions: Anti-VEGF antibody may be a promising therapeutic agent due to its beneficial effects on the survival of sepsis by decreasing inflammatory responses and endothelial permeability.Keywords
This publication has 41 references indexed in Scilit:
- Antiangiogenesis to treat cancer and intraocular neovascular disordersLaboratory Investigation, 2007
- Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortalityJournal of Experimental Medicine, 2006
- CpG Oligodeoxynucleotide Protection in Polymicrobial Sepsis Is Dependent on Interleukin‐17The Journal of Infectious Diseases, 2005
- Therapeutic Intervention and Targets for SepsisAnnual Review of Medicine, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- NAB2, a Corepressor of EGR-1, Inhibits Vascular Endothelial Growth Factor-mediated Gene Induction and Angiogenic Responses of Endothelial CellsJournal of Biological Chemistry, 2003
- Adverse Effects of the Antiangiogenic Agent Angiostatin on the Healing of Experimental Colonic AnastomosesAnnals of Surgical Oncology, 2002
- Experimental study of intraperitoneal suramin on the healing of colonic anastomosesBritish Journal of Surgery, 1999
- Vascular Endothelial Growth Factor in Patients with Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1998
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989